Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2023 Earnings Call Transcript February 22, 2024 8:00 AM ET
Company Participants
Lindsey Allen - Head, IR & Communications
Justin Klee - Co-CEO
Jim Frates - CFO
Camille Bedrosian - CMO
Josh Cohen - Co-CEO
Conference Call Participants
Charlie Young - Bank of America
Neena Bitritto-Garg - Deutsche Bank Canada
Corinne Jenkins - Goldman Sachs
Michael DiFiore - Evercore ISI
Graig Suvannavejh - Mizuho
Madhu Yennawar - Leerink Partners
Ananda Ghosh - HC Wainwright
Operator
Good morning. My name is Jenny, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals Fourth Quarter and Full Year 2023 Earnings Conference Call. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] I would now like to turn the call over to Lindsey Allen, Head, Investor Relations and Communications. Please proceed.
Lindsey Allen
Good morning, and thank you for joining us today to discuss our fourth quarter and full year 2023 earnings. With me on the call are Josh Cohen and Justin Klee, our Co-CEOs; Jim Frates, our Chief Financial Officer; and Dr. Camille Bedrosian, our Chief Medical Officer.
Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are made based on our current beliefs, plans and expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, our expectations with respect to RELYVRIO, also known as ALBRIOZA or AMX0035, statements regarding our current and planned clinical trials and regulatory developments and the expected timing thereof, our business and marketing strategy and outlook, expectations regarding results of the global Phase 3 PHOENIX trial of AMX0035 for the treatment of ALS and the impact of those results on the uptake of RELYVRIO or ALBRIOZA, the potential to expand global approvals for AMX0035 and ALS and other neurodegenerative diseases, and our expected financial performance. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements, and Amylyx disclaims any obligation to update such statements unless required by law.